178 related articles for article (PubMed ID: 2302378)
1. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
[TBL] [Abstract][Full Text] [Related]
2. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
3. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
6. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
Sato N; Brum JM; Mitsumoto H; DeBoer GE
Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
[TBL] [Abstract][Full Text] [Related]
7. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle.
Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Reyford HG; Adamantidis MM; Dupuis BA
Can J Anaesth; 1990 Jul; 37(5):556-9. PubMed ID: 2372858
[TBL] [Abstract][Full Text] [Related]
8. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Ording H
Acta Anaesthesiol Scand; 1989 Jul; 33(5):405-8. PubMed ID: 2800978
[TBL] [Abstract][Full Text] [Related]
9. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
[TBL] [Abstract][Full Text] [Related]
10. Comparison of North American and European malignant hyperthermia group halothane contracture testing protocols in swine.
Fletcher JE; Conti PA; Rosenberg H
Acta Anaesthesiol Scand; 1991 Aug; 35(6):483-7. PubMed ID: 1897341
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
[TBL] [Abstract][Full Text] [Related]
12. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
Urwyler A; Censier K; Kaufmann MA; Drewe J
Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
14. In vitro contracture tests in patients with various neuromuscular diseases.
Heytens L; Martin JJ; Van de Kelft E; Bossaert LL
Br J Anaesth; 1992 Jan; 68(1):72-5. PubMed ID: 1739572
[TBL] [Abstract][Full Text] [Related]
15. Screening for malignant hyperpyrexia.
Nelson TE; Austin KL; Denborough MA
Br J Anaesth; 1977 Feb; 49(2):169-72. PubMed ID: 836748
[TBL] [Abstract][Full Text] [Related]
16. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
Ellis FR; Halsall PJ; Hopkins PM
Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
[TBL] [Abstract][Full Text] [Related]
18. Effect of diltiazem, verapamil and dantrolene on the contractility of isolated malignant hyperpyrexia-susceptible human skeletal muscle.
Foster PS; Hopkinson KC; Denborough MA
Clin Exp Pharmacol Physiol; 1989 Oct; 16(10):799-805. PubMed ID: 2612062
[TBL] [Abstract][Full Text] [Related]
19. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
Ording H; Skovgaard LT
Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
[TBL] [Abstract][Full Text] [Related]
20. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
